National policy

Click on image to enlarge


Two crucial epidemiological observations underpin the DH strategy:

  • Half of hip fracture sufferers have broken another bone before breaking their hip
  • Approximately one sixth of postmenopausal women have suffered a fragility fracture

Thus, half of all future cases of hip fracture will come from the sixth of the population that have already suffered a fragility fracture. Implementation of NICE Technology Appraisals on osteoporosis for today’s new fragility fracture sufferers and those that have fractured in the past could halve subsequent hip fracture rates. Fracture Liaison Services (FLS) are the evidence-based model shown to consistently deliver secondary preventive care. The DH economic evaluation of FLS for the population served by an average District General Hospital concluded:

“… over a 5 year period £290,708 is saved in NHS acute and community services and local authority social care costs, against an additional £234,181 revenue costs (falling both in year 1 and covering drug therapy for five years spent by the NHS on this patient cohort).”

NHS Evidence recommends Fracture Liaison Services as a model to improve quality and reduce costs in line with the Quality, Innovation, Productivity and Prevention initiative

  • Best Practice Tariff for hip fracture (BPT): The BPT was launched in April 2010 to incentivise delivery of the hip fracture component of the DH Prevention Package. The BPT offers an incentive (of £445 per patient in 2010/11, rising to £890 per patient in 2011/12) when surgery is conducted within 36 hours of admission in combination with provision of effective ortho-geriatrician led medical care of the acute phase. BPT also requires hospitals to ensure that falls risk and bone health assessments are undertaken for all hip fracture patients, aiming to prevent secondary fractures.
  • NICE Technology Appraisals and Clinical Guidelines: NICE has published four Technology Appraisals on osteoporosis treatments:
    • NICE TA204: Denosumab ▼ for the prevention of osteoporotic fractures in postmenopausal women – October 2010
    • NICE TA161: Alendronate (review), etidronate (review), risedronate (review), raloxifene (review), strontium ranelate and teriparatide (review) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (includes a review of NICE TA87) – October 2008
    • NICE TA 160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women – October 2008

    In 2004, NICE also published Clinical Guideline 21 on the assessment and prevention of falls in older people which is the subject of a review during 2011.


 

The Breaking Point Report provided a snapshot of the current situation for women with osteoporosis in the UK.

Breaking Point described the practical steps that must be taken by healthcare professionals, policy makers and commissioners, as well as the public to prevent avoidable suffering and cost of osteoporotic fractures.


… over a 5 year period £290,708 is saved in NHS acute and community services and local authority social care costs, against an additional £234,181 revenue costs (falling both in year 1 and covering drug therapy for five years spent by the NHS on this patient cohort).

Copyright Breaking Point 2011, All Rights Reserved

Amgen Limited – Registered in England No. 2354269. Registered office: 240 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0WD, United Kingdom
Use of this website is governed by our Terms of Use, Privacy Statement and Cookie Policy.
This website is for use in the United Kingdom only
 
DMB-UKIRE-AMG-189-2011 ∙ UK/DNB/0255/11
Date of preparation: September 2011

Confirm
No
Yes